Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059   7/11/2025
6,380 USD (+1,92%)
(+1,92%)   7/11/2025

7 november 2025 · Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 · Persbericht

6 november 2025 · Evaxion announces business update and third quarter 2025 financial results · Persbericht

3 november 2025 · Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate · Persbericht

31 oktober 2025 · Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 · Persbericht

31 oktober 2025 · Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 · Persbericht

30 oktober 2025 · Evaxion raises $7.2 million, extending cash runway to second half of 2027 · Persbericht

27 oktober 2025 · Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer · Persbericht

17 oktober 2025 · Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation · Persbericht

17 oktober 2025 · Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 · Persbericht

13 oktober 2025 · Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 · Persbericht

8 oktober 2025 · Evaxion expands AI-Immunology™ platform with automated vaccine design module · Persbericht

3 oktober 2025 · Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting · Persbericht

25 september 2025 · Evaxion out-licenses vaccine candidate EVX-B3 to MSD · Persbericht

27 augustus 2025 · Evaxion to present at several conferences during the second half of 2025 · Persbericht

14 augustus 2025 · Evaxion announces business update and second quarter 2025 financial results · Persbericht

11 augustus 2025 · Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 · Persbericht

25 juli 2025 · Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 · Persbericht

11 juli 2025 · Evaxion finalizes agreement with EIB to convert debt into equity · Persbericht

1 juli 2025 · Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio · Persbericht

25 juni 2025 · Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus · Persbericht

Mijn selecties